Liang Wang

Liang Wang

Auto-generated profile, based on publicly available information

Liang Wang

Department of Structural Biology, St. Jude Children’s Research Hospital, Memphis, TN, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2024 in Science
Verified
Journal Article
Closed access
JLJiankun Lyu
Jiankun Lyu
NKNicholas Kapolka
Nicholas Kapolka
RGRyan Gumpper
Ryan Gumpper
AAAssaf Alon
Assaf Alon
LWLiang Wang
Liang Wang
BRBryan L. Roth
Bryan L. Roth
AlphaFold2 (AF2) models have had wide impact but mixed success in retrospective ligand recognition. We prospectively docked large libraries against unrefined AF2 models of the σ 2 and serotonin 2A (5-HT2A) receptors, testing hundreds of new molecules and comparing results with those obtained from docking against the experimental structures. Hit rates were high and similar for the experimental and AF2 structures, as were affinities. Success in docking against the AF2 models was achieved despite differences between orthosteric residue conformations in the AF2 models and the experimental structures. Determination of the cryo–electron microscopy structure for one of the more potent 5-HT2A ligands from the AF2 docking revealed residue accommodations that resembled the AF2 prediction. AF2 models may sample conformations that differ from experimental structures but remain low energy and relevant for ligand discovery, extending the domain of structure-based drug design.

19 June 2023 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
YCYu Chen
Yu Chen
LWLiang Wang
Liang Wang
WHWen-Tao Hou
Wen-Tao Hou
ZZZhihui Zha
Zhihui Zha
KXKang Xu
Kang Xu
YCYuxing Chen
Yuxing Chen

26 December 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
YCYu Chen
Yu Chen
LWLiang Wang
Liang Wang
WHWen-Tao Hou
Wen-Tao Hou
ZZZhi-Hui Zha
Zhi-Hui Zha
KXKang Xu
Kang Xu
YCYuxing Chen
Yuxing Chen
The activation and accumulation of human platelets contributes to hemostasis and thrombosis, the imbalance of which would cause cardiovascular diseases, an increasing threat to the global health. Human ABC transporter ABCC4 that pumps out the platelet agonist and anti-platelet drug such as aspirin, might become a promising target for preventing cardiovascular diseases. Here we solve the structures of human ABCC4 in the apo and two complexed forms, all of which adopt a typical architecture of type-IV ABC transporters in an inward-facing conformation. Structure of ABCC4 complexed with U46619, an analog of the unstable TXA 2 , provides the first structural evidence that the platelet agonist TXA 2 is also exported via ABCC4. The dipyridamole-complexed structure reveals the inhibitory mechanism of dipyridamole against ABCC4. Structural comparisons enabled us to identify a transmembrane pocket in ABCC4 that provides a defined space for the rational design of specific anti-platelet drugs.

7 October 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
LWLiang Wang
Liang Wang
TKTakeharu Kawano
Takeharu Kawano
ASAna Santa-Cruz
Ana Santa-Cruz
NPNousheen Parvaiz
Nousheen Parvaiz
AZAndrew Zorn
Andrew Zorn
GSGeorgios Skiniotis
Georgios Skiniotis
Cardiac G protein-gated inwardly rectifying potassium-K + (GIRK) channels, formed by GIRK1/4 heterotetramers or GIRK4 homotetramers, are crucial regulators of heart rate, and their dysfunction is associated with atrial fibrillation. Despite their therapeutic potential as anti-arrhythmic targets, development of selective GIRK modulators has been limited by an incomplete understanding of their structures, gating mechanisms, and pharmacology. Here, we report high-resolution structures of the GIRK4 homotetramer and of GIRK1/4 heterotetramers, revealing that they form in unexpected 1:3 and 2:2 assembly stoichiometries that we corroborate using cell-based single molecule microscopy. Electrophysiological assays and molecular dynamics simulations further show that incorporation of one or two GIRK1 subunits into GIRK4-containing channels progressively opens the helix bundle crossing (HBC) gate and increases basal channel activity. Additional structures of GIRK1/4 complexes with ML297, a small-molecule ligand selective for GIRK1-containing channels, reveal distinct GIRK1-centered intersubunit binding environments. Remarkably, ML297 inhibits GIRK1/4 channels with a 1:3 stoichiometry but potentiates channels with a 2:2 stoichiometry, establishing a direct link between subunit composition, ligand-binding environment, and pharmacological efficacy. Together, these findings provide a structural and mechanistic framework for the rational design of ligands with enhanced selectivity among cardiac and neuronal GIRK channel heterotetramers.